Therapies for chronic hepatitis B: Emerging roles for nucleoside analogues

Australian and New Zealand Journal of Medicine

Volumn 30, Issue 5, 2000, Pages 556-558

  Strasser, S I ^a   McCaughan, G W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG;

CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFECT; DRUG INDICATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; NOTE; SIDE EFFECT; TREATMENT OUTCOME; VIRUS RESISTANCE;

ANTI-HIV AGENTS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0033769634     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2000.tb00855.x     Document Type: Note

References (20)

1. Hepatitis B: Global importance and need for control
2. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
3. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan
4. The incidence of hepatitis B infection in Australia: An epidemiological review
5. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
6. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
7. Incremental increases in HBeAg seroconversion and continued ALT normalisation in Asian chronic HBV patients treated with lamivudine for four years
8. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group
9. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
10. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group
11. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
12. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
13. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
14. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
15. Combination low-dose hepatitis B immune globulin and Lamivudine therapy provides effective prophylaxis against post transplantation hepatitis B
16. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management
17. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B
18. Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient
19. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
20. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants